EGFR and neoplasm: Western blot analysis of tumor lysates indicated approximately 30% lower levels of EGFR in NCI-H3255 tumors compared to HCC827 (Figure 4), consistent with the approximately 30% lower SUV of [11C]erlotinib in NCI-H3255 tumors at 12 min after injection, the time of peak radioactivity uptake in these tumors (Figure 3).